Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recordati Industria Chimica e Farmaceutica SPA (DE:RER1)
FRANKFURT:RER1
RESEARCH TOOLSreports
Holding DE:RER1?
Track your performance easily
RER1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€43.53 - €53.22
Previous Close€49.86
Volume0.00
Average Volume (3M)68.00
Market Cap
€10.31B
Enterprise Value€11.74B
Total Cash (Recent Filing)€284.73M
Total Debt (Recent Filing)€1.72B
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 08, 2024EPS EstimateN/A
Last Dividend Ex-Date
May 20, 2024Dividend Yield2.41%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume68
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)4.51
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€49.25Price Target Upside-1.22% Downside
Rating ConsensusHold
Number of Analyst Covering4
Recordati Industria Chimica e Farmaceutica SPA News
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
24.32% Mutual Funds
5.24% Other Institutional Investors
70.36% Public Companies and
Individual Investors
RER1 FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest stock price was €43.53 and its highest was €53.22 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Currently, no data Available
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is Nov 08, 2024 which is in 43 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on Jul 30, 2024. The company reported €0.67 earnings per share for the quarter, beating the consensus estimate of €0.65 by €0.02.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Overvalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA pays a Notavailable dividend of €0.63 which represents an annual dividend yield of 2.41%. See more information on Recordati Industria Chimica e Farmaceutica SPA dividends here
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €0.67 in its last earnings report, beating expectations of €0.65. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in DE:RER1
---
Recordati Industria Chimica e Farmaceutica SPA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.06%
12-Months-Change
Fundamentals
Return on Equity
22.67%
Trailing 12-Months
Asset Growth
-0.18%
Trailing 12-Months
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth strategy. The vast majority of the company's revenue is generated in Italy, followed by France and Germany. Recordati reports two operating segments: specialty and primary care and rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.
---
RER1 Stock 12 Month Forecast
Average Price Target
€49.25
▼(-1.22% Downside)
Technical Analysis
AstraZeneca
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Recordati Industria Chimica e Farmaceutica SPA
―
Best Analysts Covering RER1
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-7.46%
reiterated a sell rating 2 months ago
Copying Charles Pitman CFA's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -7.46% per trade.
---